Physician profile
Jonathan Burress
NPI 1760415582
$43,221.76
in general payments reported to CMS, 2019-2025
35 companies · $1,480 in 2025
The $1,480 reported for 2025 was more than what 78% of Cardiovascular Disease providers received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,101 · 2020: $12K · 2021: $24K · 2022: $1,396 · 2023: $1,633 · 2024: $2,121 · 2025: $1,480.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,233 · Education: $0.54.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,232.99 |
| Education | $0.54 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Esperion Therapeutics, INC. | $34,178.07 | 2020-2022 | |
| Abbott Laboratories | $2,591.69 | 2019-2025 | Xience Skypoint, Dragonfly Opstar, Ultreon |
| Novartis Pharmaceuticals Corporation | $2,063.95 | 2019-2025 | |
| Medtronic, INC. | $989.30 | 2021-2025 | Micra, Tyrx, Azure Xt Dr Mri Surescan |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $818.39 | 2019-2025 | Lifevest |
| Amgen INC. | $341.85 | 2019-2025 | Repatha, Repatha |
| Daiichi Sankyo INC. | $251.95 | 2022-2024 | Injectafer |
| Astrazeneca Pharmaceuticals LP | $245.88 | 2019-2023 | Farxiga |
| Boehringer Ingelheim Pharmaceuticals, INC. | $212.53 | 2019-2024 | Jardiance |
| E.R. Squibb & Sons, L.L.C. | $200.89 | 2024-2025 | Camzyos, Eliquis |
| Janssen Pharmaceuticals, INC | $197.05 | 2019-2022 | |
| Boston Scientific Corporation | $189.45 | 2019-2025 | Watchman Flx, Bodyguardian |
| Pfizer INC. | $159.64 | 2019-2024 | |
| Atricure, INC. | $76.89 | 2022-2024 | |
| Actelion Pharmaceuticals US, INC. | $56.64 | 2025 | Uptravi, Opsumit |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lexicon Pharmaceuticals, INC. | $54.82 | 2023 | Inpefa |
| Cardiovascular Systems INC. | $52.53 | 2019-2020 | |
| Irhythm Technologies, INC. | $52.50 | 2023-2024 | Zio Xt Patch, Zio Monitor |
| Astellas Pharma US INC | $52.22 | 2019 | |
| Merck Sharp & Dohme LLC | $50.43 | 2022-2025 | Verquvo |
| Medtronic Vascular, INC. | $49.07 | 2019 | |
| Stryker Corporation | $43.76 | 2024 | Zipseal 24 Surgical Skin Closure Kit |
| Inari Medical, INC. | $39.65 | 2022 | |
| Sanofi-Aventis U.S. LLC | $35.47 | 2019 | |
| Philips North America LLC | $33.86 | 2019 | |
| Kowa Pharmaceuticals America, INC. | $25.78 | 2019-2021 | |
| Abiomed | $24.95 | 2020 | |
| Lantheus Medical Imaging, INC. | $24.19 | 2024 | |
| Convatec INC. | $19.82 | 2022 | |
| Elutia, INC. | $17.95 | 2022 | |
| Cook Medical LLC | $17.77 | 2020 | |
| Lundbeck LLC | $16.18 | 2020 | |
| Regeneron Healthcare Solutions, INC. | $14.25 | 2019 | |
| Amarin Pharma, INC. | $11.22 | 2020 | |
| Gilead Sciences, INC. | $11.17 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jonathan Burress listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.